Egle A - Search Results

1

Subversion of the Bcl-2 life/death switch in cancer development and therapy.

Adams JM, Huang DC, Strasser A, Willis S, Chen L, Wei A, van Delft M, Fletcher JI, Puthalakath H, Kuroda J, Michalak EM, Kelly PN, Bouillet P, Villunger A, O'Reilly L, Bath ML, Smith DP, Egle A, Harris AW, Hinds M, Colman P, Cory S. Adams JM, et al. Among authors: egle a. Cold Spring Harb Symp Quant Biol. 2005;70:469-77. doi: 10.1101/sqb.2005.70.009. Cold Spring Harb Symp Quant Biol. 2005. PMID: 16869785

2

VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia.

Egle A, Harris AW, Bath ML, O'Reilly L, Cory S. Egle A, et al. Blood. 2004 Mar 15;103(6):2276-83. doi: 10.1182/blood-2003-07-2469. Epub 2003 Nov 20. Blood. 2004. PMID: 14630790 Free article.

3

Bim is a suppressor of Myc-induced mouse B cell leukemia.

Egle A, Harris AW, Bouillet P, Cory S. Egle A, et al. Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6164-9. doi: 10.1073/pnas.0401471101. Epub 2004 Apr 12. Proc Natl Acad Sci U S A. 2004. PMID: 15079075 Free PMC article.

4

p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa.

Valente LJ, Gray DH, Michalak EM, Pinon-Hofbauer J, Egle A, Scott CL, Janic A, Strasser A. Valente LJ, et al. Among authors: egle a. Cell Rep. 2013 May 30;3(5):1339-45. doi: 10.1016/j.celrep.2013.04.012. Epub 2013 May 9. Cell Rep. 2013. PMID: 23665218 Free article.

5

TNF cytokine family: more BAFF-ling complexities.

Laâbi Y, Egle A, Strasser A. Laâbi Y, et al. Among authors: egle a. Curr Biol. 2001 Dec 11;11(24):R1013-6. doi: 10.1016/s0960-9822(01)00613-3. Curr Biol. 2001. PMID: 11747837 Free article. Review.

6

Bim and Bmf in tissue homeostasis and malignant disease.

Piñon JD, Labi V, Egle A, Villunger A. Piñon JD, et al. Among authors: egle a. Oncogene. 2008 Dec;27 Suppl 1(Suppl 1):S41-52. doi: 10.1038/onc.2009.42. Oncogene. 2008. PMID: 19641506 Free PMC article. Review.

7

Apaf-1 and caspase-9 do not act as tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast transformation.

Scott CL, Schuler M, Marsden VS, Egle A, Pellegrini M, Nesic D, Gerondakis S, Nutt SL, Green DR, Strasser A. Scott CL, et al. Among authors: egle a. J Cell Biol. 2004 Jan 5;164(1):89-96. doi: 10.1083/jcb.200310041. J Cell Biol. 2004. PMID: 14709542 Free PMC article.

8

On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.

Greil R, Egle A, Villunger A. Greil R, et al. Among authors: egle a. Leuk Lymphoma. 1998 Nov;31(5-6):477-90. doi: 10.3109/10428199809057607. Leuk Lymphoma. 1998. PMID: 9922038 Review.

9

Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy.

Sochalska M, Tuzlak S, Egle A, Villunger A. Sochalska M, et al. Among authors: egle a. FEBS J. 2015 Mar;282(5):834-849. doi: 10.1111/febs.13188. Epub 2015 Jan 23. FEBS J. 2015. PMID: 25559680 Free PMC article. Review.

10

Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status.

Egle A, Villunger A, Marschitz I, Kos M, Hittmair A, Lukas P, Grünewald K, Greil R. Egle A, et al. Br J Haematol. 1997 May;97(2):418-28. doi: 10.1046/j.1365-2141.1997.382680.x. Br J Haematol. 1997. PMID: 9163609 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

162 results

Search Page

Filters